肝硬変治療薬の世界市場2016-2020

◆英語タイトル:Global Liver Cirrhosis Market 2016-2020
◆商品コード:IRTNTR8209
◆発行会社(調査会社):Technavio
◆発行日:2016年5月6日
◆ページ数:74
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、肝硬変治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、肝硬変治療薬の世界市場規模及び予測、種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About Cirrhosis of the Liver
Cirrhosis of the liver (or liver fibrosis) is a serious condition in which the liver stops functioning properly due to damage and irreversible scarring of the liver tissue. The scarring of the tissue is often caused by long-term exposure to viral infections and toxins such as alcohol. Chronic viral hepatitis and non-alcoholic steatohepatitis can also cause liver cirrhosis. Alcohol-related medications, antiviral medications, and metal chelating agents are used in the treatment of the causes of liver cirrhosis while antibiotics, vitamins, corticosteroids, diuretics, beta-blockers, and laxatives are used for the treatment of the complications of the disease.

Technavio’s analysts forecast the global liver cirrhosis therapeutics market to grow at a CAGR of 4.36% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global liver cirrhosis therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of liver cirrhosis.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Liver Cirrhosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• F Hoffman La-Roche
• GlaxoSmithKline
• Gilead Sciences
• Johnson & Johnson
• Merck

[Other prominent vendors]
• Bristol-Myers Squibb
• Conatus Pharmaceuticals
• Gwo Xi Stem Cell Applied Technology
• Instituto Grifols
• Intercept Pharmaceuticals
• NGM Biopharmaceuticals
• Norgine
• Pharmicell
• Salix Pharmaceuticals
• Stempeutics Research

[Market driver]
• High prevalence of liver cirrhosis
• For a full, detailed list, view our report

[Market challenge]
• Adverse effects of drugs
• For a full, detailed list, view our report

[Market trend]
• Use of off-label drugs
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Etiology
• Symptoms
• Pathophysiology
• Diagnosis
• Epidemiology
• Prevention
• Treatment
• Impact of alcohol consumption on liver cirrhosis

PART 06: Pipeline portfolio
• Information on pipeline candidates
• Clinical trials for liver cirrhosis

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by type of molecule
• Biologics
• Small molecules

PART 09: Market segmentation by types of liver cirrhosis

PART 10: Market segmentation by types of liver cirrhosis treatment
• Medications to treat causes of liver cirrhosis
• Medications to treat complications of liver cirrhosis

PART 11: Geographical segmentation
• Liver cirrhosis medication market in Americas
• Market overview
• Market size and forecast
• Liver cirrhosis medication market in EMEA
• Market overview
• Market size and forecast
• Liver cirrhosis medication market in APAC
• Market overview
• Market size and forecast

PART 12: Market drivers
• High prevalence of liver cirrhosis
• Advances in technology
• High unmet medical needs
• Changes in lifestyle

PART 13: Impact of drivers

PART 14: Market challenges
• Use of alternative therapies
• Adverse effects of drugs
• Poor patient adherence
• Stringent regulatory guidelines

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Rise in public awareness
• Increase in R&D
• Use of off-label drugs
• Patient assistance programs

PART 17: Vendor landscape
• Competitive scenario
• F Hoffmann-La Roche
• GlaxoSmithKline
• Gilead Sciences
• Johnson & Johnson
• Merck
• Other prominent vendors

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Stages of liver diseases
Exhibit 03: Causes of liver cirrhosis
Exhibit 04: Diagnosis of liver cirrhosis
Exhibit 05: Effect of alcohol consumption on liver cirrhosis
Exhibit 06: Pipeline molecules for liver cirrhosis
Exhibit 07: Clinical trials by development phase
Exhibit 08: Clinical trials by trial status
Exhibit 09: Global liver cirrhosis medication market 2015-2020 ($ billions)
Exhibit 10: Five forces analysis
Exhibit 11: Four main types of liver cirrhosis
Exhibit 12: Market share by types of liver cirrhosis
Exhibit 13: Types of treatment for liver cirrhosis
Exhibit 14: Global liver cirrhosis medication market segment by geography 2015
Exhibit 15: Global liver cirrhosis medication market segment by geography 2015-2020 ($ millions)
Exhibit 16: Liver cirrhosis medication market in Americas ($ millions)
Exhibit 17: Liver cirrhosis medication market in EMEA ($ millions)
Exhibit 18: Liver cirrhosis medication market in APAC ($ billions)
Exhibit 19: Impact of drivers
Exhibit 20: Impact of drivers and challenges
Exhibit 21: F Hoffmann-La Roche: Business segmentation 2014 by revenue
Exhibit 22: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 23: F Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 24: F Hoffmann-La Roche: YoY growth and revenue of Pegasys 2012-2014 ($ billions)
Exhibit 25: F Hoffmann-La Roche: Key takeaways
Exhibit 26: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 27: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 28: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 29: GlaxoSmithKline: YoY growth and revenue of Epivir 2012-2014 ($ millions)
Exhibit 30: Gilead Sciences: Geographical segmentation by revenue 2014
Exhibit 31: Gilead Sciences: YoY revenue comparison of Sovaldi 2013-2014 ($ millions)
Exhibit 32: Gilead Sciences: YoY growth and revenue of Viread 2012-2014 ($ millions)
Exhibit 33: Gilead Sciences: Key takeaways
Exhibit 34: Johnson & Johnson: Business segmentation by revenue 2014
Exhibit 35: Johnson & Johnson: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 36: Johnson & Johnson: Geographical segmentation by revenue 2014
Exhibit 37: Johnson & Johnson: YoY growth and revenue of Incivo 2012-2014 ($ millions)
Exhibit 38: Johnson & Johnson: YoY revenue growth of Olysio 2012-2014 ($ millions)
Exhibit 39: Johnson & Johnson: Key takeaways
Exhibit 40: Merck: Business segmentation by revenue 2014
Exhibit 41: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 42: Merck: Geographical segmentation by revenue 2014
Exhibit 43: Merck: YoY growth and revenue of PegIntron 2012-2014 ($ millions)
Exhibit 44: Merck: YoY growth and revenue of Victrelis 2012-2014 ($ millions)
Exhibit 45: Merck: Key takeaways



【掲載企業】

F Hoffman La-Roche, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Merck, Bristol-Myers Squibb, Conatus Pharmaceuticals, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, NGM Biopharmaceuticals, Norgine, Pharmicell, Salix Pharmaceuticals, Stempeutics Research.

【レポートのキーワード】

肝硬変、肝硬変治療薬、肝線維症、医薬品、パイプライン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[肝硬変治療薬の世界市場2016-2020]販売に関する免責事項
★調査レポート[肝硬変治療薬の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆